|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, September 10, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring pharmaceutical company Exelixis Inc. (Nasdaq: EXEL).
The investment report on Exelixis Inc. (Nasdaq: EXEL) should be of particular interest to other pharmaceutical companies: AstraZeneca plc. (NYSE: AZN), OSI Pharmaceuticals (Nasdaq: OSIP), Biogen Idec Inc. (Nasdaq: BIIB) and Amgen Inc. (Nasdaq: AMGN).
It is available at: http://www.beaconequity.com/i/EXEL
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Exelixis Inc. (EXEL) is engaged in the development of novel small molecule drug therapies for the treatment of cancer. The Company's strategy is to leverage its biotechnologies by partnering with big pharmaceutical companies, including Bristol-Myers Squibb, Sanofi-Aventis, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals and Daiichi-Sankyo.
In the report, the analyst notes:
“If approved by the U.S. Food and Drug Administration (FDA), the market for EXEL's lead drug candidate, XL184, could reach more than $1 billion at its market saturation. XL147 and XL765 are Company's phase II drug candidates for the treatment of solid tumors, with prospects of reaching commercialization at approximately 50% following successful completion of phase II. Lead drug candidate, XL184, has a 90% chance of reaching commercialization, according to FDA statistics.
“Pharmaceutical companies with revenue of more than $1 billion include Cephalon Inc. (Nasdaq: CEPH), which trades at a market capitalization of $4.27 billion, and King Pharmaceuticals (Nasdaq: KG), which trades at a market capitalization of $2.62 billion. As of September 8, EXEL trades at a market capitalization of $673 million.”
To read the entire report visit: http://www.beaconequity.com/i/EXEL
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Beacon Equity
Jeff Bishop
(469)-252-3505
press@beaconequity.com 
Source: EmailWire.com
|
|
|
|
